# Efficacy, Safety and Tolerability of Agomelatine Sublingual Tablets in the Treatment of Major Depressive Disorder

> **NCT01110889** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 582 (actual)

## Conditions studied

- Major Depressive Disorder

## Interventions

- **DRUG:** Agomelatine (AGO178C)
- **DRUG:** Agomelatine (AGO178C)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01110889
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-05
- **Primary completion:** 2011-07
- **Final completion:** —
- **Target enrollment:** 582 (ACTUAL)
- **Last updated:** 2020-12-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01110889

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01110889, "Efficacy, Safety and Tolerability of Agomelatine Sublingual Tablets in the Treatment of Major Depressive Disorder". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01110889. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*